FRANKFURT (Reuters) – BioNTech SE on Monday said it has begun work on a vaccine suitable for Omicron, the worrying new coronavirus variant https://www.reuters.com/business/healthcare-pharmaceuticals /what-we-know-about- covid-19 variant-found-south-africa-2021-11-26 detected in South Africa, although it remains unclear if it has to do the COVID-19 shot again is set or not.
In a statement, the development of an adaptive vaccine is part of the company’s standard process for new variants, said BioNTech, which makes the vaccine alongside Pfizer.
“The first steps of developing a potential new vaccine overlap with the studies needed to assess whether a new shot is needed,” it added.
On Monday, the WHO warned the Omicron variant poses a very high risk of a global increase as more countries report cases, prompting borders to close.
BioNTech said on Friday that it expects more laboratory data over the next two weeks to help determine if an Omicron-specific vaccine is needed. Rival Moderna says it is working on redesigning its COVID-19 vaccine for future boosters.
(Reporting by Ludwig Burger; Editing by Zuzanna Szymanska)
https://wsau.com/2021/11/29/biontech-starts-work-on-omicron-specific-vaccine/ BioNTech begins research on Omicron-specific vaccine | WSAU News / Talk 550 AM · 99.9 FM